Related Experiment Video

Updated: Jul 17, 2026

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

Efficient targeted anticoagulant with active RGD motif

Qun Bi1, Xue Zhou, Xiaodong Cen

  • 1National Key Laboratory of Biomembrane and Membrane Biotechnology, College of Life Sciences, Peking University, Beijing, 100871, PR China.

Thrombosis Research
|January 16, 2007
PubMed

Insights

New RGD-hirudin anticoagulants show potent antithrombin and antiplatelet activity. These modified hirudin variants, particularly RGD-hirudin 1 and 2, demonstrate promising potential for clinical use.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Hirudin is a potent thrombin inhibitor.
  • The Arg-Gly-Asp (RGD) motif plays a crucial role in platelet aggregation.
  • Developing novel anticoagulants with enhanced efficacy is a significant clinical need.

Purpose of the Study:

  • To generate and characterize novel recombinant hirudin variants incorporating the RGD motif.
  • To evaluate the antithrombin and antiplatelet activities of these modified hirudins.
  • To explore the structural basis of RGD-hirudin activity through computational modeling.

Main Methods:

  • Chemical synthesis of RGD-hirudin variants by conjugating RGD sequences to hirudin.
  • In vitro assays to measure antithrombin and antiplatelet activities.
  • Computer simulations to analyze the structure of the active RGD motif.

Main Results:

  • Three RGD-hirudin variants (RGD-hirudin 1, 2, and 3) were successfully synthesized.
  • All variants demonstrated significant antithrombin and antiplatelet activities.
  • RGD-hirudin 1 and 2 exhibited notably lower IC50 values compared to previously reported analogs.
  • Computer simulation revealed a triangular structure for the active RGD motif.

Conclusions:

  • RGD-hirudin 1 and 2 represent promising candidates for clinical anticoagulant therapy.
  • The structural insights into the RGD motif may advance understanding of integrin-related interactions.
  • This study highlights the potential of combining hirudin with RGD motifs for improved anticoagulant drugs.

More Related Videos

Modification and Functionalization of the Guanidine Group by Tailor-made Precursors09:45

Modification and Functionalization of the Guanidine Group by Tailor-made Precursors

Published on: April 27, 2017

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...